The AAV vector-based gene therapy market is expanding across multiple therapeutic areas. Ophthalmology was one of the first successes, with approved therapies for inherited retinal dystrophies. The eye's immune-privileged nature makes it an attractive target for gene therapy.
In the adeno-associated virus vector-based gene therapy market, hematology is another major area, particularly hemophilia A and B. Liver-directed AAV therapies have shown durable expression of clotting factors, reducing bleeding episodes.
Neurology is a rapidly growing segment. Therapies for spinal muscular atrophy and Parkinson's disease are in development, though delivery to the central nervous system remains challenging. Cardiology and metabolic disorders are also emerging targets.
Each therapeutic area has distinct delivery, dosing, and safety considerations. As clinical evidence accumulates, the AAV vector-based gene therapy market is expected to diversify, with new indications driving growth and competition.
People Also Ask
-
Which therapeutic area leads AAV gene therapy? Ophthalmology and hematology are leading areas, with neurology growing rapidly.
-
Can AAV therapy treat neurological diseases? Yes, several therapies are in development, though CNS delivery remains technically challenging.
Tags: #GeneTherapyTherapeuticAreas #Ophthalmology #Hematology #Neurology #AAV #RareDisease